<DOC>
	<DOCNO>NCT01097460</DOCNO>
	<brief_summary>This open-label Phase 1 trial MM-111 combination Herceptin .</brief_summary>
	<brief_title>MM-111 Combination With Herceptin Patients With Advanced Her2 Amplified , Heregulin Positive Breast Cancer</brief_title>
	<detailed_description>Phase 1 : Safety tolerability MM-111 + Herceptin combination evaluate recommended Phase 2 dose determine .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patients must histologically cytologically confirm advanced breast cancer amplify HER2 , base archived tumor biopsy ( IHC 2+ great ) Patients must histologically cytologically confirm advanced breast cancer heregulin positive base fresh tumor tissue biopsy The patient 's cancer must recur , progress respond standard chemotherapy standard treatment . Prior therapy may include limited Herceptin , Tykerb ( lapatinib ) , anthracyclines , taxanes Patients must ≥ 18 year age Patients legal representative must able understand sign inform consent Patients may measurable ( per RECIST 1.1 ) nonmeasurable tumor ( ) ( Phase 1 ) Patients ECOG Performance Score ( PS ) 0 , 1 2 ( Phase 1 ) . Patients life expectancy least 12 week Patients must adequate bone marrow reserve Patients must adequate hepatic function Patients must adequate renal function Patients must recover effect prior surgery , radiotherapy antineoplastic therapy . Women childbearing potential well fertile men partner must agree abstain sexual intercourse use effective form contraception study 90 day follow last dose MM111 . Patients pregnant lactate Patients active infection unexplained fever &gt; 38.5°C ( 101.3° F ) screen visit first schedule day dose . Patients untreated and/or symptomatic metastatic CNS malignancy . Patients know hypersensitivity component MM111 hypersensitivity reaction fully human monoclonal antibody , include Herceptin . Patients receive recent antitumor therapy include : Treatment Herceptin within 28 day prior first schedule day dose MM111 Investigational therapy administer within 28 day prior first schedule day dose MM111 ( Dosing less 28 day ' since receive investigational therapy acceptable time interval equal least five halflives investigational agent pass . ) Any standard chemotherapy , Tykerb ( lapatinib ) radiation within 14 day ( passed time actual anticipated toxicity ) prior first schedule dose MM111 Patients previously receive MM111 Patients NYHA Class III IV congestive heart failure LVEF &lt; 50 % Patients history allogeneic transplant Patients know HIV , hepatitis B C ( patient previously treat hepatitis C undetectable viral load , consider eligible trial ) Patients medical psychological condition deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>HER2/HER3</keyword>
	<keyword>Bispecific Antibody</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Advanced Breast Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>HER2 Positive Breast Cancer</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Herceptin</keyword>
</DOC>